Trulicity and Mounjaro are not the same medication. They contain different active ingredients, work through different mechanisms, and produce different levels of blood sugar and weight reduction. Trulicity (dulaglutide) activates one hormone pathway, while Mounjaro (tirzepatide) activates two. That distinction drives meaningful differences in how well each drug works and who it’s prescribed for.
How Each Drug Works
Trulicity contains dulaglutide, which mimics a gut hormone called GLP-1. This hormone signals your pancreas to release insulin when blood sugar rises, slows digestion so glucose enters your bloodstream more gradually, and reduces appetite by acting on hunger signals in the brain. Trulicity targets only the GLP-1 receptor, making it a single-target drug.
Mounjaro contains tirzepatide, which was engineered by building GLP-1 activity into a second gut hormone called GIP. The result is a single molecule that activates both the GIP and GLP-1 receptors. GIP plays its own role in insulin release and fat metabolism, so combining both pathways in one drug creates effects that go beyond what either hormone achieves alone. Research published in JCI Insight describes tirzepatide as an “imbalanced” dual agonist, meaning it leans more heavily on GIP activity while still engaging GLP-1. This dual approach is why Mounjaro tends to outperform single-target GLP-1 drugs like Trulicity in clinical trials.
Blood Sugar Control
Both drugs are approved for type 2 diabetes, but Mounjaro lowers blood sugar more effectively. In real-world data comparing tirzepatide to other GLP-1 drugs, patients new to treatment saw an average A1c reduction of 1.3% with tirzepatide versus 0.9% with the comparator. Among patients who had previously used other diabetes medications, the gap remained: 0.9% versus 0.6%. Those differences were statistically significant.
The SURPASS-CVOT trial directly compared tirzepatide against dulaglutide in patients with type 2 diabetes and existing heart disease. The trial was designed to show whether Mounjaro could beat Trulicity not just on blood sugar but on cardiovascular outcomes as well. That head-to-head design reflects how confident researchers were that tirzepatide would at minimum match dulaglutide’s performance.
Weight Loss
Weight loss is where the gap between these two drugs becomes most dramatic. In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight loss in overweight or obese patients without diabetes over 72 weeks: 15% of body weight at the lowest dose (5 mg), 19.5% at 10 mg, and 20.9% at the highest dose (15 mg). The placebo group lost just 3.1%. For a 220-pound person, the highest dose translates to roughly 46 pounds lost over about a year and a half.
Trulicity does cause some weight loss, but it was never designed or approved as a weight management drug. Its weight reduction is more modest, typically in the range of 5 to 8 pounds in clinical trials. Mounjaro’s active ingredient, tirzepatide, is also sold under the brand name Zepbound specifically for chronic weight management in people without diabetes.
Dosing Differences
Both medications are injected once a week under the skin, usually in the thigh, abdomen, or upper arm. The similarities largely end there.
- Trulicity starts at 0.75 mg per week as a starter dose, then typically moves to 1.5 mg. It can be increased further to 3 mg or a maximum of 4.5 mg depending on your response.
- Mounjaro starts at 2.5 mg per week, then steps up to 5 mg. From there it can be titrated in 2.5 mg increments up to a maximum of 15 mg.
In both cases, the starting dose is meant to let your body adjust and is not expected to fully control blood sugar on its own. Your prescriber will increase the dose gradually, usually every four weeks, based on how well you tolerate the medication and how your blood sugar responds.
Side Effects
The side effect profiles overlap considerably because both drugs act on GLP-1 receptors. Nausea, vomiting, diarrhea, decreased appetite, and constipation are the most common complaints with either medication. These tend to be worst during dose increases and often improve after a few weeks at a stable dose.
Because Mounjaro activates two receptor pathways and is available at higher potency, some patients experience more pronounced gastrointestinal symptoms, particularly at the upper dose range. The gradual titration schedule for both drugs exists specifically to minimize these effects. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help.
Approved Uses and Availability
Trulicity has been on the market since 2014 and is approved for type 2 diabetes. It also carries an FDA-approved indication for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease, a distinction based on dedicated cardiovascular outcome trial data.
Mounjaro received FDA approval for type 2 diabetes in 2022. Its active ingredient is also approved under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Trulicity does not have a weight management indication.
Can You Switch Between Them?
Switching from Trulicity to Mounjaro is common, particularly for patients who need stronger blood sugar control or greater weight loss. Because the drugs work on overlapping pathways, the transition is generally straightforward. Most prescribers will start Mounjaro at its lowest dose (2.5 mg) regardless of what Trulicity dose you were on, then titrate up. You can typically start Mounjaro the week after your last Trulicity injection.
Switching in the other direction, from Mounjaro to Trulicity, is less common but may happen due to insurance coverage, cost, or tolerability. Both drugs are expensive at list price, and coverage varies widely between insurance plans. Trulicity has been available longer, so it may have broader formulary coverage in some cases, while Mounjaro’s newer status sometimes means prior authorization requirements or higher copays.